Liminatus Pharma, Inc. · NASDAQ:LIMN
Liminatus Pharma — Investor Presentation (June 2025)
22 slides from Liminatus Pharma's investor presentation, Jun 24, 2025
Slide 1: Next Generation CD47 Blockade with Liminatus Pharma, Innobation Bio
Crafting the Future of Healing for Patients Next Generation CD47 Blockade with Liminatus Pharma, Innobation Bio
Slide 2: Disclaimer
Disclaimer This presentation (this “Presentation”) has been assembled by Liminatus Pharma Limited, including its affiliates (the “Company”), and is provided to certain investors and analysts for informational purposes only. This Presentation is exclusively intended for the recipient and may not be d
Slide 3: Index
Crafting the Future of Healing for Patients Investment Highlights Pipeline overview An Experienced Leadership Team and Board Members Cancer Treatment INDEX
Slide 4: Investment Highlights
4 Liminatus Pharma, LLC Investment Highlights 01 Leading Next - Generation CD47 Blockade • Proprietary IBA101 overcomes anemia and thrombocytopenia issues of first - generation CD47 antibodies • Demonstrated selective binding (immune cells vs. RBC) for an improved safety profile Cancer Therapeutics
Slide 5: Pipeline Overview
5 Liminatus Pharma, LLC Phase III Phase II Phase I IND Pre - clinical Indications Candidate Solid Cancer Anti - CD47 Blockade (IBA101) T.B.D. * CAR - T Therapy (T.B.D.) T.B.D. * Companion Diagnosis (T.B.D.) Pipeline Overview 02 * Liminatus Pharma plans to in - license companion diagnostic technologi
Slide 6: An Experienced Leadership Team and Board Members
6 Liminatus Pharma, LLC An Experienced Leadership Team and Board Members 03 • Liminatus Pharma is an immunotherapy company focused on the development of a CD47 - blocking antibody for the treatment of solid tumors. • Preclinical development of the CD47 blockade antibody has been completed, and prepa
Slide 7: Cancer Treatment
01 02 03 04 05 06 Cancer Treatment Crafting the Future of Healing for Patients
Slide 8: Cancer Therapeutics
8 Liminatus Pharma, LLC 1. Cancer Therapeutics 04 • For successful cancer immunotherapy treatment, the Cancer Immunity Cycle must operate smoothly through close cooperation betw een innate immunity and T cell - centered adaptive immunity, with the patient's immune system maintaining continuous activ
Slide 9: Don't Eat Me Signal and CD47 Blockade
9 Liminatus Pharma, LLC 2. Don’t Eat Me Signal and CD47 Blockade 05 “Don’t Eat Me” & “Eat Me” Signals Landry MR, Walker JM, Sun C. Exploiting Phagocytic Checkpoints in Nanomedicine: Applications in Imaging and Combination Therapies. Front Chem. 2021 Mar 3;9:642530 • “Don’t Eat Me” Signal CD47 on the
Slide 10: Mechanism of CD47-SIRPα Checkpoint and Anti-CD47 Blockade
10 Liminatus Pharma, LLC 2. Don’t Eat Me Signal and CD47 Blockade 06 Mechanism of CD47 – SIRPα Checkpoint and Anti - CD47 Blockade • Cis - and Trans - Interactions Inhibit Phagocytosis Trans - interaction : CD47 on tumor cells binds SIRP α on macrophages across the intercellular synapse, delivering
Slide 11: Selective binding of IBA101 sparing RBCs and platelets
11 Liminatus Pharma, LLC 3. IBA101; Next Generation Anti - CD47 Blockade 07 Selective binding of IBA101 to CD47 on immune and tumor cells, sparing RBCs and platelets IBA101 preferentially binds CD47 on nucleated immune and tumor cells, while sparing CD47 on anucleate red blood cells and platelets. •
Slide 12: IBA101 preferentially binds immune cells, not RBCs and platelets
12 Liminatus Pharma, LLC 3. IBA101; Next Generation Anti - CD47 Blockade 08 IBA101 preferentially binds to immune cells, but negligibly to RBCs and platelets IBA101 does not bind to RBCs CC2C6 PBMC Whole blood IBA101 IBA101
Slide 13: IBA101 does not induce RBC lysis
13 Liminatus Pharma, LLC 3. IBA101; Next Generation Anti - CD47 Blockade 09 IBA101 does not induce RBC lysis IBA101 does not induce RBC lysis. IBA101 CC2C6 which binds to RBCs Hemagglutination assay with human RBCs 0 0.1 0.5 1.0 5.0 10 25 ( μ g /mL)
Slide 14: IBA101 exclusively binds to human CD47
14 Liminatus Pharma, LLC 3. IBA101; Next Generation Anti - CD47 Blockade 10 IBA101 exclusively binds to human CD47 Membrane Proteome Analysis of IBA101 • Assay Partner : Integral Molecular (Philadelphia, PA) • Library : > 6,000 distinct human membrane proteins displayed on a proteome array • Outcome
Slide 15: Synergistic anti-tumor effects of IBA101 and anti-PD-1 mAb
15 Liminatus Pharma, LLC 3. IBA101; Next Generation Anti - CD47 Blockade 11 Synergistic anti - tumor effects of IBA101 and anti - PD - 1 mAb in humanized mouse tumor model ▪ MC38 - hCD47 ▪ s.c. , 1 10 6 cells 0 hCD47 - hSIRPa KI ▪ mAbs ▪ Every 5 days ▪ 200 μ g/injection 10 15 20 Efficacy of IBA101 (
Slide 16: IBA101 synergy with I/O drugs boosting T cell responses
16 Liminatus Pharma, LLC 3. IBA101; Next Generation Anti - CD47 Blockade 12 IBA101 synergistically enhances anti - tumor responses with I/O drugs boosting T cell responses Versatile Synergy of IBA101 with Multiple T - Cell – Boosting Checkpoint Modulators . • In a human SIRPα/CD47 double knock - in
Slide 17: Non-Clinical Safety Profile of IBA101 in Non-Human Primates
17 Liminatus Pharma, LLC 3. IBA101; Next Generation Anti - CD47 Blockade 13 Non - Clinical Safety Profile of IBA101 in Non - Human Primates Non - Clinical Safety Profile of IBA101 in Non - Human Primates . • Study: Charles River Laboratories Study No. 3627 - 011 (GLP - compliant) • Test Article: IBA
Slide 18: Powerful and Safe Treatment Strategy
18 Liminatus Pharma, LLC 3. IBA101; Next Generation Anti - CD47 Blockade 14 Powerful and Safe Treatment Strategy • PD - 1/PD - L1 inhibitors boost T cell activity, but their increased interferon - gamma levels can suppress macrophage differentiation , thereby reducing the initial immune response. In
Slide 19: Development Strategy of Anti-CD47 Blockade (IBA101)
19 Liminatus Pharma, LLC 15 4. Development Strategy of Anti - CD47 Blockade (IBA101) Changes in Lung Cancer Treatment I/O Drugs • New inhibitors, etc. Standard Therapy • Surgery • Chemotherapy • Radiotherapy • +PD - 1/PD - L1 inhibitors • +New inhibitors I/O Drugs • CTLA - 4 inhibitor • PD - 1/PD -
Slide 20: Market Size and Growth Prospects of CD47 Blockade Therapeutics
20 Liminatus Pharma, LLC 16 5. Market Size and Growth Prospects of CD47 Blockade Therapeutics Market Outlook for CD47 Blockade • CD47 blockade represents one of the most promising pipelines for achieving excellent synergistic effects with the T cell boosters currently under development. Therefore, a
Slide 21: Key Development Milestones
21 Liminatus Pharma, LLC 17 6. Key Development Milestones Key Development Milestones CD47 mAb 3A5 mAb development and humanization Biochemical analysis 2020.12 2021.06 2022.3Q 2020.01 Ph1 Mono - and Combi - therapy Lung cancer IBA101 PD - 1/PD - L1 blockade Safety and efficacy Phase I IND packaging
Slide 22: Crafting the Future of Healing for Patients
Crafting the Future of Healing for Patients